Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway

BACKGROUND: Lung cancer is one of the most common and deadly tumors around the world. Targeted therapy for patients with certain mutations, especially by use of tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR), has provided significant benefit to patients. However,...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Yong-An, Ma, Ting, Zhang, Xue-Yan, Cheng, Xiang-Song, Olajuyin, Ayobami-Matthew, Sun, Zhi-Fu, Zhang, Xiao-Ju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498592/
https://www.ncbi.nlm.nih.gov/pubmed/31073278
http://dx.doi.org/10.1186/s12935-019-0836-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498592/
https://www.ncbi.nlm.nih.gov/pubmed/31073278
http://dx.doi.org/10.1186/s12935-019-0836-8

Ejemplares similares